Injective doubles down on deflation — but traders remain unconvinced
Injective’s community has given the green light to an aggressive deflationary overhaul, approving the “supply squeeze” proposal almost unanimously. IIP-617 passed with 99.89% of votes in favor, kicking off what the Layer 1 says is “a new chapter of INJ” aimed at dramatically shrinking token supply and making INJ one of the most deflationary crypto assets over time.
What changed
- Proposal: IIP-617, first proposed on January 16, doubles the protocol’s total supply reduction rate — a 100% increase to the ongoing buyback-driven deflation mechanism.
- Mechanics: The plan halves emissions (staking rewards) and ramps up token buybacks. Previously, Injective used collected fees to fund buybacks, removing over 6.8 million INJ from circulation to date.
- Token basics: INJ launched with a max supply of 100,000,000 and functions as the ecosystem’s governance token. Its annual inflation/emissions vary dynamically between 5% and 10%, depending on an 85% staking ratio.
Why opinions are split
Buyback programs are contentious across crypto. Some projects market them as direct “token value accrual,” while critics argue buybacks merely burn capital if they don’t translate into sustained price appreciation — a critique voiced by token teams such as Jupiter (JUP). Whether Injective’s twin approach of cutting emissions and boosting buybacks will prove accretive remains to be seen.
Market reaction so far
The update delivered only a short-lived pop. INJ spiked about 4% after the announcement but later relinquished gains as broader markets turned sour — Bitcoin slipped toward $90K after reports of U.S. tariffs on Europe weighed on sentiment. On the spot chart, INJ fell under $5 and briefly revisited December lows near $4.40; analysts note it could retest support around $4.42 if selling pressure continues.
Futures activity offers a muted picture
Futures demand hasn’t followed tokenomics optimism:
- Futures CVD (Cumulative Volume Delta) grew increasingly negative from January 15 onward, deteriorating even after the “supply squeeze” news.
- Open interest has barely budged, holding near $25 million.
Bottom line
Injective has enacted one of the more ambitious on-chain deflationary rollouts, but market indicators suggest traders are pricing in broader macro and crypto risk rather than the tokenomics upgrade. Whether the tighter supply profile will eventually drive sustained upside for INJ remains uncertain.
Disclaimer: This article is for informational purposes and not investment advice. Cryptocurrency trading carries substantial risk; do your own research before making decisions. © 2026 AMBCrypto
Read more AI-generated news on: undefined/news
